Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IGC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIGC Pharma raises $514k via convertible notes with 25% discount conversion upon default
Filed April 20, 2026 · Period ending April 14, 2026 · ~1 min read
Key Changes
-
high
IGC issued two promissory notes totaling $585k principal ($514k net after discounts) to FirstFire and Vanquish, maturing in 2027 with 12% interest. If IGC defaults, holders can convert debt to stock at 75% of the lowest price over prior 10 trading days—a 25% discount that could trigger significant dilution.
Item 1.01 verify on EDGAR → -
medium
Conversion is capped at 4.99% ownership per holder and 19.99% of total shares outstanding without shareholder approval per NYSE American rules. These limits reduce immediate dilution risk but don't eliminate it if defaults occur over time.
Item 1.01 verify on EDGAR → -
medium
The $514k net proceeds will fund general working capital, suggesting IGC needed near-term liquidity for operations. The notes carry original issue discounts totaling $71k (12% of gross proceeds).
Item 1.01 verify on EDGAR → -
low
Any shares issued upon conversion will be unregistered restricted securities under Section 4(a)(2) exemption, meaning they cannot be freely traded immediately.
Item 3.02 verify on EDGAR →
Summary
IGC Pharma raised $514,000 in net proceeds through two convertible promissory notes with FirstFire Global and Vanquish Funding, disclosing the transactions in an 8-K filed April 20.
The notes mature in 2027 and carry 12% annual interest, but the critical detail for shareholders is the default-triggered conversion feature: if IGC fails to meet its obligations, lenders can convert their debt into common stock at a 25% discount to recent market prices. This "death spiral" structure could force significant dilution if the company encounters financial stress.
Retail investors should understand that while conversion caps limit immediate damage—no holder can exceed 4.99% ownership and total conversions are capped at 19.99% without shareholder vote—these protections don't eliminate risk if defaults happen repeatedly or the stock price declines. The need for this relatively small financing ($514k net) for general working capital may signal tight liquidity. Watch IGC's next quarterly report for cash burn rates and any disclosure of payment difficulties. If the company misses payments or amends these notes, conversion and dilution could begin quickly given the steep discount terms.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”).
IGC issued a promissory note to FirstFire with $346,910 principal (including $39,910 original issue discount) for $307,000 cash, maturing April 10, 2027. The note carries 12% interest and is prepayable at any time with written notice.
Added in current filing · verify on EDGAR →
Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total aggregate principal amount of $238,050, which includes an original issue discount of $31,050. The aggregate purchase price paid by VFG for the Note is $207,000. The Note matures on March 30, 2027 (the “Maturity Date”).
IGC issued a promissory note to Vanquish Funding Group with $238,050 principal (including $31,050 original issue discount) for $207,000 cash, maturing March 30, 2027. The note carries 12% interest and is prepayable at any time with written notice.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company intends to use the proceeds from the Notes for general working capital purposes.
The $514,000 net proceeds from both notes will be used for general working capital, indicating the company needed near-term liquidity for operations.
Event · Item 2.03 — Creation of a Direct Financial Obligation
IGC Pharma disclosed creation of a direct financial obligation, with details incorporated by reference from Item 1.01.
Added in current filing · verify on EDGAR →
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01 above is incorporated by reference into this Item 2.03.
The company disclosed the creation of a direct financial obligation or off-balance sheet arrangement. The specific terms and details are referenced in Item 1.01 of the filing, which was not provided in the excerpt. This indicates IGC Pharma has entered into a new debt arrangement, credit facility, or similar financial commitment that creates a material obligation.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Item 3.02 — Unregistered Sales of Equity Securities filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Any Conversion Shares issuable upon conversion of the Note will be issued pursuant to the exemption from the registration requirements of the Securities Act provided by Section 4(a) (2) thereof, as a transaction not involving a public offering.
IGC Pharma disclosed that conversion shares from a convertible note will be issued without SEC registration, relying on the private placement exemption under Section 4(a)(2) of the Securities Act. This means the shares cannot be freely traded and are restricted securities. The filing references Item 1.01 for additional details about the underlying note transaction, but that section is not included in the provided excerpt.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Securities Purchase Agreement, dated April 10, 2026, by and between IGC Pharma, Inc. and FirstFire Global Opportunities Fund, LLC.
IGC Pharma entered into a securities purchase agreement with FirstFire Global Opportunities Fund on April 10, 2026. This agreement is accompanied by a promissory note for $346,910 in principal, indicating the company raised debt financing from this investor.
Added in current filing · verify on EDGAR →
Promissory Note, dated April 10, 2026, issued by IGC Pharma, Inc. to FirstFire Global Opportunities Fund, LLC in the aggregate principal amount of $346,910.
IGC Pharma issued a promissory note to FirstFire Global for $346,910 in principal. The terms, interest rate, maturity date, and conversion features are not disclosed in this 8-K filing but would be detailed in the attached exhibit.
Added in current filing · verify on EDGAR →
Securities Purchase Agreement, by and between IGC Pharma, Inc. and Vanquish Funding Group Inc.
IGC Pharma entered into a second securities purchase agreement with Vanquish Funding Group. This agreement is accompanied by a promissory note for $238,050 in principal, representing additional debt financing.
Added in current filing · verify on EDGAR →
Promissory Note, issued by IGC Pharma, Inc. to Vanquish Funding Group Inc. in the aggregate principal amount of $238,050.
IGC Pharma issued a promissory note to Vanquish Funding for $238,050 in principal. Combined with the FirstFire note, the company raised approximately $585,000 in debt financing, which may indicate capital needs or ongoing operations funding.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify